Author: Site Editor Publish Time: 2026-08-31 Origin: Site
From August 25 to 27, CPHI Korea 2026 was held at COEX Convention & Exhibition Center in Seoul, South Korea. The Biocom Pharma team visited the exhibition to engage with pharmaceutical companies and industry partners across APIs, finished dosage forms, pharmaceutical R&D, and manufacturing services, gaining first-hand insights into market needs in Korea and East Asia while advancing customer collaboration and international business development.
During the exhibition, the Biocom Pharma team held discussions with existing and prospective partners on key topics including international pharmaceutical registration strategies, regulatory and quality requirements, pharmaceutical R&D, and manufacturing services.
The team also exchanged views on the progress of selected cooperation projects, evolving customer requirements, and potential pathways for future collaboration.
In parallel, the team visited key exhibition areas to gain a deeper understanding of developments in the Korean and broader East Asian pharmaceutical markets, including emerging market trends, customer needs, and industry dynamics. These first-hand insights will support future market development and project execution.
International pharmaceutical registration strategies and regulatory compliance
Alignment with international regulatory and quality standards
API and finished dosage R&D and manufacturing capabilities
Progress of existing cooperation projects and future customer requirements
Driven by R&D and innovation, Biocom Pharma has developed capabilities spanning API and finished dosage R&D and industrialization.
In recent years, the company has continued to strengthen its international development capabilities across R&D, regulatory affairs, quality, manufacturing, and supply, enabling it to better address the requirements of different markets and customers.
For Biocom Pharma, entering international markets is more than an expansion of business scope. It is also an opportunity to benchmark its R&D, quality, manufacturing, and delivery capabilities against higher international standards.
South Korea and the broader East Asian pharmaceutical markets feature mature regulatory frameworks and high expectations for product quality, R&D standards, regulatory compliance, and supply reliability. These markets therefore remain an important focus of Biocom Pharma's international development strategy.
By engaging directly with customers, understanding market needs, and advancing practical cooperation, Biocom Pharma continues to translate its R&D and industrialization capabilities into higher-quality products and services.
Through closer engagement with international partners, Biocom Pharma aims to strengthen market understanding, build long-term trust, and expand its presence across global pharmaceutical markets.
The visit to South Korea represents another concrete step in Biocom Pharma's efforts to deepen cooperation in East Asia and advance its internationalization strategy.
Looking ahead, Biocom Pharma will continue to build on scientific R&D, maintain quality and regulatory compliance as a foundation, and ensure reliable supply and delivery.
The company will further strengthen long-term cooperation with pharmaceutical companies and partners worldwide, create greater customer value through professional capabilities, and support the global availability of high-quality pharmaceutical products through continuous innovation.
